Compounding Chemotherapy Market Report 2026

Compounding Chemotherapy Market Overview

• Compounding Chemotherapy market size has reached to $6.11 billion in 2025 • Expected to grow to $8.2 billion in 2030 at a compound annual growth rate (CAGR) of 6% • Growth Driver: he Rise In Cancer Cases Drives The Growth Of The Market Due To Increasing Need For Personalized Chemotherapy Solutions • Market Trend: Advanced Automation Enhances Safety And Precision In Cancer Drug Preparation • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Compounding Chemotherapy Market?

Compounding chemotherapy refers to the customized preparation of chemotherapy drugs by trained pharmacists or technicians to meet the specific dosage, formulation, or combination requirements of individual patients. This process involves the safe handling, mixing, and labeling of cytotoxic medications in a controlled and sterile environment to ensure accuracy and patient safety. The main drug types of compounding chemotherapy are cytotoxic drugs, hormonal agents, immunomodulatory agents, targeted therapies, and supportive care drugs. Cytotoxic drugs are medications that kill or damage cells, commonly used in cancer treatment to destroy rapidly dividing cancer cells. These can be administered through various routes such as intravenous, oral, subcutaneous, intramuscular, and intrathecal. The compounding process may utilize technologies both with and without robotic arms. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, and are carried out in diverse settings such as hospital compounding, compounding pharmacies, specialty clinics, and homecare settings.

What Is The Compounding Chemotherapy Market Growth Forecast?

The compounding chemotherapy market size is expected to see strong growth in the next few years. It will grow to $8.2 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to development of automated and robotic compounding systems, expansion of homecare chemotherapy services, rising investment in sterile pharmacy infrastructure, increasing regulatory compliance for personalized medicine, growth in targeted therapies and immunomodulatory agents. Major trends in the forecast period include growing adoption of personalized chemotherapy formulations, integration of robotic compounding systems, expansion of homecare and specialty clinic compounding, rising focus on sterile and contamination-free environments, increased demand for supportive care drug compounding.

Global Compounding Chemotherapy Market Segmentation

1) By Drug Type: Cytotoxic Drugs, Hormonal Agents, Immunomodulatory Agents, Targeted Therapies, Supportive Care Drugs 2) By Route Of Administration: Intravenous, Oral, Subcutaneous, Intramuscular, Intrathecal 3) By Technology: With Robotic Arms, Without Robotic Arms 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By Compounding Setting: Hospital Compounding, Compounding Pharmacies, Specialty Clinics, Homecare Settings Subsegments: 1) By Cytotoxic Drugs: Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, Topoisomerase Inhibitors 2) By Hormonal Agents: Estrogen Antagonists, Androgen Deprivation Therapy Agents, Aromatase Inhibitors, Progestins, Gonadotropin-Releasing Hormone Agonists 3) By Immunomodulatory Agents: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Interleukins, Cytokines, Immune System Activators 4) By Targeted Therapies: Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Poly Polymerase Inhibitors 5) By Supportive Care Drugs: Antiemetics, Erythropoiesis-Stimulating Agents, Bone-Modifying Agents, Pain Management Drugs

What Is The Driver Of The Compounding Chemotherapy Market?

The increasing prevalence of cancer cases is expected to propel the growth of the compounding chemotherapy market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The rising prevalence of cancer cases is primarily due to unhealthy lifestyles, such as poor diet, lack of physical activity, smoking, excessive alcohol consumption, and prolonged exposure to environmental pollutants, which significantly raise the risk of developing various types of cancer. Compounding chemotherapy helps cancer treatment by enabling personalized medication formulations tailored to individual patient needs, improving efficacy and minimizing side effects. For instance, in October 2025, according to the National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023, an average of 972 per day, which is 8,605 more than in 2022. Therefore, the increasing prevalence of cancer cases drives the growth of the compounding chemotherapy industry.

Key Players In The Global Compounding Chemotherapy Market

Major companies operating in the compounding chemotherapy market are Baxter International Inc., Fresenius Kabi AG, Option Care Health Inc., ICU Medical Inc., Fagron NV, BioScrip Inc., B. Braun Melsungen AG, Medisca Pharmaceutique Inc., Central Admixture Pharmacy Services Inc., Icon Group Holdings Pty Ltd, Avella Specialty Pharmacy, McGuff Compounding Pharmacy Services Inc., Epicur Pharma LLC, PharMEDium Services LLC.

Global Compounding Chemotherapy Market Trends and Insights

Major companies operating in the compounding chemotherapy market are focusing on developing innovative solutions, such as robotic chemotherapy automation systems, to enhance accuracy, safety, and efficiency in personalized cancer treatment preparation. Robotic chemotherapy automation systems are advanced machines designed to accurately and safely prepare personalized chemotherapy doses by automating the compounding process, reducing human error and contamination risks. For instance, in February 2024, Simplivia Healthcare Ltd., an Israel-based healthcare technology company, launched Smart Compounders Advanced Systems to automate and streamline the preparation of cytotoxic (chemotherapy) drugs. These systems handle the compounding of cytostatics and antibodies with a capacity of 20 to 40 preparations per hour, incorporating automatic gravimetric verification and documentation to ensure high accuracy. They significantly minimize pharmacy staff’s exposure to hazardous substances and are designed to integrate effortlessly into existing laminar airflow (LAF) cabinets or isolators without requiring any modifications.

What Are Latest Mergers And Acquisitions In The Compounding Chemotherapy Market?

In June 2025, H.I.G. Capital LLC, a US-based capital market company, acquired ITH Group Limited for $70 million. With this acquisition, H.I.G. Capital LLC aims to support ITH Group’s organic growth, expand its production capacity, and enhance its digital pharmacy services. ITH Group Limited is a UK-based company that specializes in and provides aseptic compounding services, including chemotherapy preparation.

Regional Insights

North America was the largest region in the compounding chemotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Compounding Chemotherapy Market?

The compounding chemotherapy market consists of revenues earned by entities by providing services such as labeling and packaging services, dose verification and clinical review, home infusion support services, cold chain logistics and delivery services, and clinical trials drug support. The market value includes the value of related goods sold by the service provider or included within the service offering. The compounding chemotherapy market also includes sales of chemotherapy drugs, compounding devices, infusion bags and syringes, personal protective equipment, and cleanroom and isolator systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Compounding Chemotherapy Market Report 2026?

The compounding chemotherapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the compounding chemotherapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.